Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 4/20 | 0.42 |
| ▸ | GJA1 | P17302 | 3/20 | 0.42 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21754810 | 0.88 | GJB2 (0.43) | GJB2GJA1PDE2ASSTR4SSTR1 | |
| SCHEMBL19227794 | 0.86 | PDE2A (0.48) | GJB2PDE2ASSTR4SSTR1SSTR2 | |
| SCHEMBL15481891 | 0.86 | GJB2 (0.42) | GJB2GJA1PDE2ASSTR4SSTR1 | |
| SCHEMBL15481850 | 0.85 | GJB2 (0.46) | GJB2GJA1PDE2ASSTR4SSTR1 | |
| SCHEMBL16756868 | 0.84 | GJB2 (0.47) | GJB2GJA1PDE2ASSTR4SSTR1 | |
| SCHEMBL26354122 | 0.83 | HTR1A (0.48) | GJB2PDE2ASSTR4SSTR1SSTR2 | |
| SCHEMBL6809981 | 0.75 | SSTR4 (0.49) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL15481846 | 0.75 | GJB2 (0.41) | GJB2GJA1PDE2ASSTR4SSTR1 | |
| SCHEMBL17320855 | 0.74 | HTR1A (0.50) | GJB2SSTR4SSTR1SSTR2SSTR3 | |
| SCHEMBL15481960 | 0.74 | GJB2 (0.42) | GJB2GJA1PDE2ASSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | FUJIFILM CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | TYMS, TYMP, RRM2B | GJB2 3998/4885GJA1 3982/4885PDE2A 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.